Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

"Prehistoric relics" as targets for vaccination against cancer

02.09.2013
Researchers at the Paul-Ehrlich-Institut have succeeded in using a peculiarity of cancer cells for targeted immunological attack: While endogenous retroviruses are inactive in healthy cells, cancer cells produce proteins of these viruses.

With a vaccine directed against endogenous retroviruses, the progression of tumour growth could be significantly inhibited in a mouse model. The prophylactic vaccination could even prevent the development of tumours. The results of this research project were reported in the online edition of PLoS ONE dated 30 August 2013 (11 p.m. CET).


The murine renal carcinoma cell line Renca. On the left: without HERV-K envelope protein expression. On the right: genetically modified Renca cells with HERV-K envelope protein (in red).


Source: PEI - The image is available with 300 dpi (4,7x13,7 cm) - please ask the PEI Press and information office

Human endogenous retroviruses (HERV) entered the human genome millions of years ago and have been passed on from generation to generation. The human genome contains several thousand such endogenous retrovirus genes. As a rule, the genes of HERV are mute, i.e. they do not produce proteins. Researchers of the Paul-Ehrlich-Institut and other groups have already been able to show that an increase in expression of genes of one group of these retroviruses occurs in HIV infected individuals but also in the tumour cells of various types of cancer. The HERV group could be identified as HERV-K/HML-2(hom), or for short, HERV-K. Professor Dr Barbara Schnierle and her co-workers in the Virology Division of the Paul-Ehrlich-Institut now wanted to know whether the specific gene activity of HERV-K could be used therapeutically to fight cancer cells in a targeted manner. To protect healthy cells, it is required to identify structures as targets which are only displayed on cancer cells.

For their investigations, Professor Barbara Schnierle, head of the Section "AIDS, New and Emerging Pathogens", and her co-workers used a murine kidney cell line (Renca). This cell line had been genetically modified in such a way that the cells produced (human) HERV-K envelope proteins to emulate the situation of the HERV-positive human cancer cells as accurately as possible. Mice which received an i.v. administration of these cells developed lung metastases within a short period of time.

For the "vaccination" against these tumours, the researchers used the modified vaccinia virus Ankara (MVA), an attenuated virus which cannot replicate after inoculation. In addition, Professor Schnierle and her co-workers had inserted the gene for the HERV-K envelope protein into the MVA genome. After the inoculation, the gene is read in the cells and the envelope protein is formed. It is presented to the immune system as antigen and an immune response can be induced.

Then the PEI scientists performed investigations to establish whether their "vaccine" could be used both for therapeutic and for prophylactic purposes: For the therapeutic approach, they first injected the genetically modified mouse cancer cells, then waited ten days until lung metastases were formed and then treated part of the mice with the MVA vaccine. The tumours grew considerably more slowly in the vaccinated animals and fewer metastases were observed than in the non-vaccinated animals. However, complete tumour remission was not achieved.

With regard to the prophylactic vaccination, the effect was even more significant: Here, the animals were at first vaccinated twice with the virus (days 0 and 21), and the cancer cells were administered twelve days later. The animals thus vaccinated were protected entirely from tumour development – no metastases could be identified.

"The findings have shown for the first time that the HERV-K envelope protein could be a useful target for the development of a vaccine, and may be able to provide new options for the treatment of various tumours" explained Professor Schnierle.

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines in Langen in the federal state of Hessen, is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and veterinary vaccines. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the varied and many tasks performed at the institute. The PEI, with its roughly 800 staff, also has advisory functions at a national level (federal government, federal states (Länder)), and at an international level (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0072756 Publication (Fulltext)

http://www.pei.de/EN/information/journalists-press/press-releases/2013/04-prehistoric-relics-targets-vaccination-against-cancer.html

Press Release on the PEI-Website

Dr. Susanne Stöcker | idw
Further information:
http://www.pei.de

More articles from Life Sciences:

nachricht Toward a 'smart' patch that automatically delivers insulin when needed
18.01.2017 | American Chemical Society

nachricht 127 at one blow...
18.01.2017 | Stiftung Zoologisches Forschungsmuseum Alexander Koenig, Leibniz-Institut für Biodiversität der Tiere

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>